Skip to main content

Isis Licenses Antisense Tools to Merck

NEW YORK, Feb. 21 - Isis Pharmaceuticals has struck a deal with Merck to provide the pharmaceutical giant with antisense tools for drug-target validation, the company said on Thursday.

 

Under the agreement, Merck will use Isis antisense techniques to probe the biological function of genes of interest, and ascertain their utility as potential drug targets.

 

The two companies have other collaborations: Isis licensed a type 2 diabetes drug candidate to Merck in 2001, and the two firms are partnering in a hepatitis C drug discovery program.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.